Medical Care Technologies Inc. Unveils AI Facial Analysis for Early Diabetes Detection

Rhea-AI Summary

Medical Care Technologies (OTC:MDCE) has announced the development of an innovative AI Facial Health Risk Estimator for early diabetes detection. The technology analyzes facial biomarkers including skin tone irregularities, microvascular patterns, and elasticity loss to predict Type 2 diabetes risk before clinical diagnosis.

The non-invasive system uses predictive algorithms to assess diabetes susceptibility through facial analysis, potentially enabling earlier interventions and better patient outcomes, according to CEO Marshall Perkins.

Positive

• Development of innovative AI-powered diabetes detection technology
• Non-invasive early detection method could enable preventive interventions
• Technology has potential to identify diabetes years before clinical diagnosis

Negative

• No clinical validation data or accuracy rates provided
• Early-stage technology without proven market adoption
• No regulatory approval status mentioned

MESA, ARIZONA / ACCESS Newswire / September 24, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) announced a breakthrough in diabetes detection with its AI Facial Health Risk Estimator.

The platform extracts subtle facial biomarkers-including skin tone irregularities, microvascular patterns, and elasticity loss-which correlate with early insulin resistance and Type 2 diabetes risk. By layering these signals with predictive algorithms, MDCE's system delivers a personalized, non-invasive forecast of diabetes susceptibility.

"This technology can possibly identify diabetes years before it's diagnosed in the clinic," said Marshall Perkins, CEO of MDCE. "By enabling earlier interventions, we can likely reduce complications and improve patient outcomes."

Company Websites: www.medicalcaretechnologies.com | www.mdcestock.com

About Medical Care Technologies Inc.
Medical Care Technologies Inc. (OTC PINK:MDCE) provides AI-driven preventive healthcare solutions, offering non-invasive, personalized risk assessments for systemic, ocular, and dermatological conditions.

Safe Harbor Statement:
This press release contains forward-looking statements, which involve risks and uncertainties that may cause actual results to differ materially.

Contact:

Investor Relations
Medical Care Technologies Inc.
info@infiniteauctions.com
Website: www.mdcestock.com

SOURCE: Medical Care Technologies Inc. (OTC PINK:MDCE)

View the original press release on ACCESS Newswire

FAQ

What is MDCE's new AI Facial Health Risk Estimator technology?

MDCE's AI Facial Health Risk Estimator is a technology that analyzes facial biomarkers including skin tone irregularities, microvascular patterns, and elasticity loss to predict Type 2 diabetes risk before clinical diagnosis.

How does Medical Care Technologies' AI diabetes detection system work?

The system works by extracting subtle facial biomarkers and using predictive algorithms to analyze skin tone irregularities, microvascular patterns, and elasticity loss, which correlate with early insulin resistance and Type 2 diabetes risk.

What are the benefits of MDCE's AI facial analysis for diabetes detection?

The technology offers non-invasive early detection of diabetes risk, potentially identifying the condition years before clinical diagnosis, enabling earlier interventions and improved patient outcomes.

Who is the CEO of Medical Care Technologies (MDCE)?

Marshall Perkins is the CEO of Medical Care Technologies Inc.

What is the potential impact of MDCE's AI diabetes detection technology?

The technology could potentially enable earlier diabetes interventions and improve patient outcomes by identifying diabetes risk years before traditional clinical diagnosis.